Table I.
Main characteristics and results of the eligible studies.
| First authors (Refs.) | Journal | Year | Country | Methods | Duration of follow-up (months) | Cut-off point (high/low) | No. of patients | No. of deceased/alive/lost | HR estimation | Quality assessment (0–8) |
|---|---|---|---|---|---|---|---|---|---|---|
| de Silva Rudland (15) | Clin Cancer Res | 2006 | UK | IHC | 216 | ≥1% (143/148) | 291 | − | RR+95 %CI | 5 |
| Kim (16) | J Korean Med Sci | 1998 | Korea | IHC | 160 | 儥5% (221/32) | 253 | 52/153/38 | RR+95 %CI | 5 |
| Ribeiro-Silva A and Oliveira da Costa (25) | Int J Biol Markers | 2008 | Brazil | IHC | − | ≥1% (65/35) | 100 | − | 5 | |
| Wang (31) | Radiology | 2010 | China | IHC | − | Score ≥2 (92/49) | 141 | − | − | 7 |
| Rudland (17) | Cancer Res | 2002 | UK | IHC | 228 | >5% (221/112) | 333 | 168/165/- | RR+95 %CI | 6 |
| Pang (18) | Cancer Epidemiol | 2013 | China | IHC | 92 | Score ≥2 (119/51) | 170 | − | HR+95 %CI | 4 |
| Wang (19) | Eur J Clin Invest | 2008 | China | IHC | 62.4 | Score >4 (33/84) | 117 | − | Survival curves | 5 |
| Tuck (9) | Int J Cancer | 1998 | Canada | IHC | 195.6 | Score >4 (11/143) | 154 | 45/109/- | Survival curves | 4 |
IHC, immunohistochemistry; RR, risk ratio; HR, hazard ratio; CI, confidence interval.